PK Stat analysis for Levothyroxine sodium studies for USFDA submission [Design Issues]

posted by jag009  – NJ, 2017-10-24 07:45 (2348 d 00:13 ago) – Posting: # 17909
Views: 2,714

Hi,

❝ OGD is not mentioned about exclusion of subjects from Pharmacokinetic and statistical analysis, after baseline correction if subject having more-than 5% of Cmax on pre-dose concentration. This criteria we can apply for endogenous products or not?


Why now? Theoretically speaking after baseline correction the amount of drug in the system is "ought" to be attributed to the drug products.

J

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
96 visitors (0 registered, 96 guests [including 9 identified bots]).
Forum time: 06:58 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5